We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Biomedical Tattoo Detects Cancer-Associated Hypercalcemia

By HospiMedica International staff writers
Posted on 01 May 2018
A new study describes how a mole-like synthetic implant recognizes the elevated levels of calcium in the blood associated with incipient prostate, lung, colon, and breast cancer tumors.

Developed by researchers at ETH Zurich (Switzerland) and the University of Basel (Switzerland), the so-called early warning system is comprised of an encapsulated gene network integrated into human body cells implanted under the skin, where it constantly monitors blood calcium levels. More...
When calcium levels exceed a pre-determined threshold, a synthetic signaling cascade expresses transgenic tyrosinase, which triggers the production of melanin in the genetically modified cells. The skin then forms a brown mole that is visible to the naked eye.

The researchers validated the design in wild-type mice inoculated with hypercalcemic breast and colon adenocarcinoma cells. The mice, which were implanted with the subcutaneous encapsulated engineered cells, all developed tattoos, whereas no tattoos were seen in animals inoculated with normo-calcemic tumor cells. The study also confirmed that the synthetic biomedical mole could not only be detected with the naked eye, but could also optically quantified. All animals remained asymptomatic throughout the 38-day experimental period. The study was published on April 18, 2018, in Science Translational Medicine.

“It recognizes the four most common types of cancer--prostate, lung, colon, and breast cancer--at a very early stage, namely when the level of calcium in the blood is elevated due to the developing tumor,” said senior author Professor Martin Fussenegger, PhD, of the ETH department of biosystems science and engineering. “An implant carrier should then see a doctor for further evaluation after the mole appears. It is no reason to panic; the mole does not mean that the person is likely to die soon.”

“It is intended primarily for self-monitoring, making it very cost effective. However, for those who would prefer not to deal with the constant stress, an implant can also be used that develops a mark visible only under a red light,” concluded Professor Fussenegger. “The disadvantage is that the service life of such an implant is limited. Encapsulated living cells last for about a year, according to other studies. After that, they must be inactivated and replaced.”

Calcium is an essential element vital to the health of the muscular, circulatory, and digestive systems; is indispensable to the building of bone; and supports synthesis and function of blood cells. For example, it regulates the contraction of muscles, nerve conduction, and the clotting of blood. As a result, intra- and extracellular calcium levels are tightly regulated by the body. Cancer can cause hypercalcemia by bone degradation, releasing excess calcium into the blood; some tumors can produce proteins that mimic parathyroid hormone; and others can affect the ability of the kidneys to remove excess calcium.

Related Links:
ETH Zurich
University of Basel


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Gold Member
Blood Gas Analyzer
i-Check200
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients with acute kidney injury. (Photo courtesy of Fresenius Medical Care)

U.S. Launch Expands Kidney Replacement Therapy Options With Integrated Anticoagulation

Critically ill patients with acute kidney injury often require continuous kidney replacement therapy in intensive care units. During these extracorporeal treatments, careful anticoagulation management... Read more

Surgical Techniques

view channel
Image: IMX742 CMOS image sensor for single-use endoscopes (Photo courtesy of Sony Semiconductor Solutions Corporation)

Miniature Image Sensor Enables Digital Imaging in Single-Use Endoscopes

Disposable single-use endoscopes are increasingly used to help reduce infection risk and the burden of post-procedure reprocessing and equipment management. As insertion sections become thinner, endoscopic... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.